Bioventus (NASDAQ:BVS) Shares Down 6.3% – What’s Next?

Shares of Bioventus Inc. (NASDAQ:BVS) dropped 6.3% on Thursday . The company traded as low as $9.91 and last traded at $10.2530. Approximately 90,046 shares were traded during trading, a decline of 76% from the average daily volume of 382,108 shares. The stock had previously closed at $10.94.

Analysts Set New Price Targets

BVS has been the topic of a number of analyst reports. CJS Securities initiated coverage on Bioventus in a research report on Friday, March 27th. They set a “market outperform” rating and a $14.00 price objective on the stock. Barrington Research reaffirmed an “outperform” rating and set a $14.00 price objective on shares of Bioventus in a research report on Friday. Cantor Fitzgerald raised Bioventus to a “strong-buy” rating in a research report on Wednesday, March 4th. Finally, Craig Hallum lifted their price objective on Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, March 6th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $14.00.

Bioventus Price Performance

The firm has a 50 day moving average of $9.66 and a 200-day moving average of $8.47. The company has a market cap of $775.20 million, a P/E ratio of 22.63, a P/E/G ratio of 1.21 and a beta of 0.72. The company has a current ratio of 1.69, a quick ratio of 1.13 and a debt-to-equity ratio of 1.08.

Bioventus (NASDAQ:BVS) last issued its earnings results on Wednesday, May 6th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.06. The company had revenue of $132.09 million for the quarter. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, equities research analysts predict that Bioventus Inc. will post 0.79 EPS for the current year.

Insider Transactions at Bioventus

In related news, Director Michelle Mcmurry-Heath sold 12,000 shares of Bioventus stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $8.79, for a total transaction of $105,480.00. Following the sale, the director owned 44,997 shares of the company’s stock, valued at approximately $395,523.63. This trade represents a 21.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 33.00% of the company’s stock.

Institutional Trading of Bioventus

A number of large investors have recently added to or reduced their stakes in BVS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Bioventus by 7.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock worth $211,000 after acquiring an additional 1,538 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in Bioventus by 19.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 162,412 shares of the company’s stock worth $1,486,000 after acquiring an additional 26,103 shares during the last quarter. Legal & General Group Plc increased its stake in Bioventus by 100.9% in the 2nd quarter. Legal & General Group Plc now owns 71,409 shares of the company’s stock worth $473,000 after acquiring an additional 35,873 shares during the last quarter. Rhumbline Advisers increased its stake in Bioventus by 20.6% in the 2nd quarter. Rhumbline Advisers now owns 65,093 shares of the company’s stock worth $431,000 after acquiring an additional 11,133 shares during the last quarter. Finally, Marshall Wace LLP increased its stake in Bioventus by 32.5% in the 2nd quarter. Marshall Wace LLP now owns 211,695 shares of the company’s stock worth $1,401,000 after acquiring an additional 51,951 shares during the last quarter. Institutional investors own 62.94% of the company’s stock.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.